1 Circulating serum miRNAs predict response to platinum chemotherapy in high-grade serous

- 2 ovarian cancer
- 3
- 4 Kazuhiro Suzuki¹, Akira Yokoi^{1,2}, Juntaro Matsuzaki³, Kosuke Yoshida^{1,2}, Yusuke Yamamoto⁴,
- 5 Tomoyasu Kato⁵, Mitsuya Ishikawa⁵, Takahiro Ochiya⁶, Hiroaki Kajiyama¹
- 6
- ¹ Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, 65
- 8 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
- ² Institute for Advanced Research, Nagoya University, Furo-cho, Chikusa-ku, 464-8601 Nagoya
- 10 464-8601, Japan
- ³ Division of Pharmacotherapeutics, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen,
- 12 Minato-ku, Tokyo 105-8512, Japan
- ⁴Laboratory of Integrative Oncology, National Cancer Center Research Institute, 5-1-1 Tsukiji,
- 14 Chuo-ku, Tokyo, 104-0045, Japan
- ⁵ Department of Gynecology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo,
- 16 104-0045, Japan
- ⁶ Department of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical
- 18 University, 6-1-1 Nishishinjuku, Shinjyuku-ku Tokyo 160-8402, Japan
- 19

20 Corresponding author

- 21 Akira Yokoi, M. D., Ph. D.
- 22 Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine,
- 23 Tsuruma-cho 65, Showa-ku, Nagoya 466-8550, Japan
- 24 Tel: +81-52-744-2261
- 25 Fax: +81-52-744-2268

26 E-mail: <u>ayokoi@med.nagoya-u.ac.jp</u>

28 Abstract

29	Background: Platinum chemotherapy is the cornerstone of treatment for high-grade serous ovarian
30	cancer (HGSOC); however, validated biomarkers that can accurately predict platinum response are
31	lacking. Based on their roles in the underlying pathophysiology, circulating microRNAs are potential,
32	noninvasive biomarkers in cancer. In the present study, we aimed to evaluate the circulating miRNA
33	profiles of patients with HGSOC and to assess their potential utility as biomarkers to predict
34	platinum response.
35	Methods: Pretreatment serum samples collected from patients who received platinum chemotherapy
36	for stage III-IV HGSOC between 2008 and 2016 were analyzed using miRNA microarray. LASSO
37	logistic regression analysis was used to construct predictive models for treatment-free interval of
38	platinum (TFIp).
39	Results: The median follow-up was 54.6 (range, 3.5–144.1) months. The comprehensive analysis of
40	2,588 miRNAs was performed in serum samples of 153 eligible patients, and predictive models were
41	constructed using a combination of circulating miRNAs with an area under the receiver operating
42	characteristic curve of 0.944 for TFIp > 1 month, 0.637 for TFIp \ge 6 months, 0.705 for TFIp \ge 12
43	months, and 0.938 for TFIp \geq 36 months. Each predictive model provided a significant TFIp
44	classification ($p = 0.001$ in TFIp >1 month, $p = 0.013$ in TFIp ≥ 6 months, $p < 0.001$ in TFIp ≥ 12
45	months, and $p < 0.001$ in TFIp ≥ 36 months).
46	Conclusion: Circulating miRNA profiles has potential utility in predicting platinum response in
47	patients with HGSOC and can aid clinicians in choosing appropriate treatment strategies.
48	Keywords:
49	high-grade serous ovarian cancer, platinum response, miRNA, biomarker

51 Introduction

According to the GLOBOCAN estimates, 313,959 new ovarian cancer cases and 207,252 ovarian 52 53 cancer-related deaths occurred worldwide in 2020 [1]. High-grade serous ovarian cancer (HGSOC), 54 the main epithelial ovarian cancer subtype [2], is already in advanced stage at diagnosis in most cases; therefore, the 5-year survival rate of advanced-stage HGSOC is approximately 30% [3]. The 55 56 standard treatment strategy for HGSOC is primary debulking surgery followed by chemotherapy or neoadjuvant chemotherapy with subsequent interval debulking surgery [4]. The introduction of 57 58 bevacizumab and Poly(ADP-ribose) polymerase inhibitors (PARPi) has expanded the spectrum of 59 available treatment alternatives, but consistent therapy efficacy is limited [5, 6]. Platinum chemotherapy remains the most vital therapeutic agent for the treatment of both primary and 60 recurrent HGSOC [4]. 61

Treatment-free interval of platinum (TFIp) is a commonly used decision criterion for 62 63 platinum rechallenge [7]. Similarly, the TFIp status has been used to classify patients in clinical trials 64 on ovarian cancer [8], [9]. However, the efficacy of platinum rechallenge was clearly demonstrated 65 in several phase II trials, which showed that platinum chemotherapy was no longer effective patients with a TFIp of <6 months [10, 11], indicating that a TFIp of <6 months was not a consistent predictor 66 67 of response to platinum chemotherapy. There are various chemotherapy options for ovarian cancer, 68 such as platinum chemotherapy with or without the addition of bevacizumab or maintenance therapy 69 with or without the addition of bevacizumab and PARPi. For an expected short duration of TFIp with 70 platinum chemotherapy alone, the addition of bevacizumab or enhanced maintenance therapy should 71 be selected with the expectation of additional therapeutic benefit. In contrast, for an expected long 72 duration of TFIp with platinum chemotherapy alone, the patient may choose not to receive any additional therapy or maintenance therapy. Therefore, accurate prediction of TFIp is essential for 73 74 treatment selection. Currently, validated biomarkers that predict response to platinum chemotherapy 75 in clinical settings are lacking.

76	MicroRNAs (miRNAs) are endogenous, small, noncoding, single-stranded RNAs that
77	regulate target gene expression and play vital roles in cancer progression [12, 13]. Importantly,
78	miRNAs are released from cells to stably exist in body fluids by escaping RNase degradation.
79	Circulating miRNAs in body fluids are wrapped up by extracellular vesicles, thereby intervening in
80	cell-to-cell communication in both the original and the distant microenvironments [14-16]. We have
81	previously demonstrated the potential role of circulating miRNAs as noninvasive diagnostic
82	biomarkers for ovarian cancer, with high accuracy and prognostic ability found in high-grade serous
83	carcinoma and ovarian clear cell carcinoma [17-19]. Recent studies have also reported the utility of
84	miRNA expression profiles in predicting therapeutic response in cancer [20, 21].
85	In the present study, we aimed to determine the utility of circulating miRNA profiles as
86	noninvasive biomarkers to predict platinum response in HGSOC. Thus, we investigated the
87	association between platinum response and circulating miRNA profiles before platinum therapy by
88	analyzing patients who did not receive bevacizumab or PARPi as first-line therapy to specifically
89	determine platinum response. Therefore, the present study provides novel evidence on the utility of
90	circulating miRNA profiles as noninvasive biomarkers to predict platinum response in HGSOC.
91	Materials and methods
92	Patient selection
93	This is a retrospective cohort study based on miRNA profiles identified in a previous study and on
94	the clinical information of the patients. In a previous study, we collected 4,046 serum samples from
95	patients with ovarian tumors and healthy controls admitted or referred to the National Cancer Center
96	Hospital between 2008 and 2016 [17]. Data are available from the NCBI database under the
97	accession number GSE106817. The present study included the pretreatment serum samples of 442
98	patients with ovarian tumors. The clinical information of patients, such as age, histologic subtype,
99	International Federation of Gynecology and Obstetrics stage, residual tumor volume, administration
100	of neoadjuvant or adjuvant chemotherapy, recurrence, and death, was retrospectively reviewed by

101 accessing the database of the Department of Gynecology of the National Cancer Center Hospital 102 (Tokyo, Japan). Patients with stage III-IV HGSOC were included after the exclusion of patients who 103 underwent surgery or chemotherapy before serum collection and those with a history of other cancers. 104 Follow-up was performed at least every 3 months for 2 years after the last platinum treatment. At the 105 time of follow-up, computed tomography was performed after at least every 6 months. Tumors were 106 evaluated using contrast-enhanced computed tomography every two cycles. The response to 107 chemotherapy was evaluated according to the Response Evaluation Criteria in Solid Tumors 1.1. 108 The present study was approved by the National Cancer Center Hospital Institutional 109 Review Board (approval no. 2015-376, 2016-29), and all participants provided written informed 110 consent. 111 miRNA expression analysis 112 The serum samples stored in the National Cancer Center Biobank were used for comprehensive 113 miRNA expression analysis using the 3D-Gene miRNA labeling kit and the 3D-Gene Human 114 miRNA Oligo Chip (Toray Industries Inc., Tokyo, Japan), which was designed to detect 2,588 115 miRNA sequences registered in miRBase (release 21) [22]. To that end, total RNA was extracted 116 from 300 µL of the serum samples using the 3D-Gene RNA extraction reagent (Toray Industries Inc., 117 Tokyo, Japan). In the present study focusing on circulating miRNAs released by ovarian cancer cells, 118 miRNAs were selected according to the criteria described in our previous study [17]. Among a total 119 of 2,038 miRNAs, 858 miRNAs were detected in extracellular vesicles derived from at least one

120 ovarian cancer cell line. Among these, 210 miRNAs that were identified based on a human serum

121 dataset were included in the final analysis [17].

122 Statistical analysis

In the present study, TFIp was defined as the time interval from the last platinum treatment to the time of initial tumor progression or last contact and overall survival was defined as the time interval from initial treatment to the time of death from any cause (Supplementary Figure 1).

126 Sensitivity, specificity, and accuracy of the circulating miRNAs in predicting TFIp were determined 127 using receiver operating characteristic (ROC) curve analysis and the area under the ROC curve 128 (AUC) was calculated. The ROC analysis was used to determine the TFIp with the best power, which 129 was used to develop a predictive model for platinum response. Thus, predictive index-positive cases 130 were considered as patients with a TFIp >X months. The sensitivity showed the predictive rate of 131 TFIp longer than X months, and the specificity showed the predictive rate of TFIp less than X months. To calculate sensitivity, specificity, and accuracy, optimal cutoff values were set based on 132 133 the maximum point of the sum of sensitivity and specificity, i.e., Youden index. The 95% confidence 134 interval (95% CI) of the AUC was calculated and plotted in the ROC curve. Two-group comparison 135 was performed using Welch's *t*-test. LASSO logistic regression analysis was performed using the R 136 software (version 4.3.0; R Foundation for Statistical Computing, http://www.R-project.org), 137 compute.es (version 0.2-4), glmnet (version 2.0-3), hash (version 2.2.6), MASS (version 7.3-45), 138 mutoss (version 0.1-10), and pROC (version 1.8). ROC curves were compared using the DeLong test. Pearson's χ^2 , Welch's t tests, and one-way analysis of variance were performed using SPSS Statistics 139 140 (version 29; IBM Corp., Armonk, NY, USA). Kaplan–Meier curves were used for the analysis of 141 TFIp and were compared using the generalized Wilcoxon test. A two-sided p value <0.05 were 142 considered statistically significant for all analyses.

143 **Results**

A total of 422 serum samples of patients with ovarian tumors were analyzed using the miRNA
microarray to obtain the comprehensive miRNA expression profiles of patients. After the exclusion
of serum samples from 262 patients with other ovarian cancer subtypes, 14 patients with stage I–II
cancer, 11 patients with insufficient clinical information, and 2 patients with low-quality microarray
results, the profiles of 153 patients were included in the final analysis (Figure 1).
The patient characteristics are summarized in Table 1. Briefly, all patients received

150 cytoreductive surgery and adjuvant chemotherapy, which typically included carboplatin plus

151 paclitaxel, without bevacizumab or PARPi. The median follow-up period was 54.6 (range,

152 3.5–144.1) months. The groups were created according to the initial TFIp, and 143, 122, 84, and 30

patients had TFIp > 1, ≥ 6 , ≥ 12 , and ≥ 36 months, respectively.

154 Selection of circulating miRNA candidates, and construction of predictive models

- 155 A total of 210 miRNAs selected as candidate biomarkers according to the method described in our
- previous report were used in combination with other prognostic factors included in Table 1 [17]. In
- 157 each group, a predictive model was constructed using the LASSO logistic regression analysis. The
- results are summarized in Table 1, and the details of the predictive model are shown in
- 159 Supplementary Table 1. Only one model was selected to predict TFIp in each group based on
- 160 DeLong test. The most appropriate predictive model was expressed as follows: model TFIp > 1
- 161 month: exp Y / $(1 + \exp Y)$ | Y = $(-0.43074 \times miR-1228-5p) + (-0.2713 \times miR-1273g-3p) + (0.2881)$
- $162 \times miR-3917) + (-0.15449 \times miR-3940-5p) + (0.03679 \times miR-4708-3p) + (-1.00381 \times miR-4739) + (-1.0$

163 $(-0.0285 \times \text{miR-486-5p}) + (0.47157 \times \text{miR-498}) + (0.35716 \times \text{miR-6088}) + (0.09762 \times \text{miR-608}) +$

- 164 miR-6872-3p) + 13.9039 and model TFIp \geq 6 months: exp Y / (1 + exp Y) | Y = (0.04331 ×
- 165 miR-4708-3p) + 1.0617 and model TFIp \geq 12 months: exp Y / (1 + exp Y) | Y = (-0.0426 \times
- 166 miR-3141 + (0.01861 × miR-3928-3p) + (0.0129 × miR-6766-5p) + (0.0094 × miR-7108-3p) +

167 0.31159, and model TFIp \geq 12 months: exp Y / (1 + exp Y) | Y = (-0.0125433 \times miR-1181) +

 $(0.1067349 \times miR-1254) + (0.0015947 \times miR-1268b) + (-0.3771727 \times miR-187-5p) + (0.0360527 \times miR-187-5p) + (0.0360527 \times miR-1268b) + (-0.3771727 \times miR-187-5p) + (0.0360527 \times miR-1268b) + (-0.3771727 \times miR-187-5p) + (0.0360527 \times miR-187-5p) + (0.0360577 \times miR-187-5p) + (0.03605777 \times miR-187$

169 miR-191-5p + (-0.0984009 × miR-3141) + (0.0233745 × miR-3195) + (-0.5606837 × miR-3197) +

170 $(0.2415774 \times \text{miR}-320a) + (0.1046963 \times \text{miR}-342-5p) + (0.0502296 \times \text{miR}-3928-3p) + (0.0009486)$

$$171 \times miR-422a) + (0.0050783 \times miR-4419b) + (0.05179 \times miR-4429) + (0.4470169 \times miR-4447) + (0.05179 \times miR-4429) + (0.0470169 \times miR-4447) + (0.05179 \times miR-4429) + (0.05179 \times miR-4449) + (0.05179 \times miR-4429) + (0.05179 \times miR-4449) + (0.05179 \times miR-449) + (0.05179 \times miR-49) + (0.05179 \times miR-49) + (0.05179 \times miR-49) + (0$$

 $172 \quad (0.0210486 \times miR-4449) + (-0.9951068 \times miR-4463) + (-0.0335096 \times miR-4484) + (0.0152364 \times miR-4484) + (0.0152864 \times miR-484) + (0.012864 \times miR-484) + (0.0164 \times miR-484) + (0.0152864$

- 173 miR-4515) + (0.0870314 × miR-4640-5p) + (0.2338915 × miR-4675) + (0.0864322 × miR-486-5p)
- $174 + (0.5827542 \times miR-557) + (0.0782236 \times miR-6088) + (-0.1712249 \times miR-642a-3p) + (0.1380852)$
- 175 \times miR-6766-3p) + (-0.3991616 \times miR-6799-5p) + (-0.2738122 \times miR-6808-5p) + (0.0531576 \times

177 miR-718 + (-0.5161003 × miR-8089) + (-0.1219326 × miR-887-3p) + (0.0626341 × miR-939-5p)

+ 19.9189978. The AUC of most appropriate predictive models for each model was as follows:

model TFIp > 1 month: 0.944 (95% CI: 0.896-0.992) for the group with TFIp > 1 month, model

180 TFIp \geq 6 months: 0.637 (95% CI: 0.526–0.748) for the group with TFIp \geq 6 months, model TFIp \geq

181 12 months: 0.705 (95% CI: 0.622–0.787) for the group with TFIp \geq 12 months, and model TFIp \geq 36

182 months: 0.938 (95% CI: 0.891–0.985) for the model with TFIp \geq 36 months (Figure 2).

183 Further potentials for predictive models

184 Each model was applied to all subgroups and AUCs were calculated. Model TFIp > 1 month: AUC

of 0.683 for the group with TFIp \geq 6 months, 0.603 for TFIp \geq 12 months, and 0.618 for TFIp \geq 36

186 months. Model TFIp \geq 6 months: 0.631 for TFIp > 1 month, 0.570 for TFIp 12 \geq months, and 0.563

187 for TFIp \ge 36 months. Model TFIp \ge 12 months: 0.757 for > 1 month, 0.698 for TFIp 6 \ge months,

and 0.659 for TFIp \geq 36 months. Model TFIp \geq 36 months: 0.624 for > 1 month, 0.641 for TFIp 6 \geq

189 months, and 0.645 for TFIp \geq 12 months (Supplementary Table 2). The predictive models for each

190 TFIp group were re-evaluated by dividing each group into those with TFIp shorter and longer than

the cutoff value. As shown in Figure 3A, there was a significant difference in each group (p = 0.001

in model TFIp > 1 month, p = 0.013 in model TFIp ≥ 6 months, p < 0.001 in model TFIp ≥ 12

193 months, and p < 0.001 in model TFIp \ge 36 months) (Figure 3A, Supplementary Figure 2A). Upon

examining the model score transition for each patient, we observed a tendency of decreasing model

score when the actual TFIp was lower than the predicted TFIp (Figure 3B).

196 **Reassessment of the predictive model**

197 Pearson's correlation coefficients were calculated between TFIp and model score for each model.

- 198 TFIp was positively correlated with all models (r = 0.170 in model TFIp > 1 month, r = 0.047 in
- 199 model TFIp \geq 6 months, r = 0.256 in model TFIp \geq 12 months, and r = 0.630 in model TFIp \geq 36
- 200 months) (Supplementary Figure 2A). Kaplan–Meier curves were constructed after stratifying patients

201 into high and low groups based on the cutoff value of each model score. The Kaplan–Meier curves

202 indicated that patients with a high model score had significantly longer TFIp than those with a low

model score (p = 0.006 in model TFIp > 1 month, p = 0.003 in model TFIp ≥ 12 months, and p < 12

204 0.001 in model TFIp \geq 36 months) (Supplementary Figure 2B). Therefore, the three models have the

205 potential to predict early recurrence, regardless of each cutoff value.

206 Discussion

Accurate prediction of platinum response is fundamentally important in the clinical management of patients with HGSOC. Previous studies have explored the efficacy of platinum chemotherapy by categorizing patients as those who were platinum-sensitive and those who were platinum-resistant based on a TFIp of 6 months [23, 24]. In the present study, we evaluated the expected TFIp before platinum chemotherapy. The AUC values for model TFIp > 1 month and model TFIp \ge 36 months were 0.944 and 0.938, respectively. The inclusion of circulating miRNA profiles in these analyses demonstrated their ability in accurately predicting TFIp.

The mechanisms underlying platinum chemotherapy resistance in patients with HGSOC 214 215 have been extensively evaluated [25-28]. Platinum resistance is not straightforward and is considered 216 a complex biologic process. Therefore, the combination of factors, rather than a single factor, is a 217 reasonable approach to develop biomarkers. In the present study, the miRNAs selected as predictive 218 factors were different and multiple in each model, which may reflect platinum-resistant and 219 -sensitive pathologies. Model TFIp \geq 12 months appeared to be versatile, with an AUC \geq 0.69 for all 220 subgroups, but model TFIp > 1 month for the group with TFIp > 1 month and model TFIp ≥ 6 221 months for TFIp \geq 6 months were the most appropriate, each with an AUC of \geq 0.9. The miRNA with 222 the strongest negative impact in model TFIp > 1 month was miR-4739. With demonstrated 223 involvement in the VEGFA/PI3K/AKT pathway, miR-4739 has been reported to play an 224 antioncogenic role in pancreatic cancer [29]. The miRNA with the strongest impact in model TFIp \geq 225 6 months was miR-4708-3p. According to miRDB, one of the targets of miR-4708-3p is interleukin

226 22, which has been previously reported to be involved in chemotherapy resistance in lung and breast 227 cancers [30-32]. The miRNA with the strongest impact in model TFIp \geq 12 months was miR-3141, 228 which directly targets transforming growth factor- β , which has demonstrated roles in platinum 229 response in ovarian cancer [33-35].

230 Currently, there is not one standard definition for therapeutic response, although biomarkers 231 to predict therapeutic response have been investigated in ovarian cancer. In clinical trials, the typical 232 primary endpoints are indicators such as overall and progression-free survival and response rate. 233 Indicators that might define platinum treatment response in ovarian cancer include TFIp, response 234 rate, and progression-free survival [24, 36, 37]. Biomarkers that can predict platinum response should be able to predict TFIp in first-line therapy because TFIp is expected. Second- or third-line 235 236 chemotherapy might provide TFIp; however, recurrence and progression might still occur during 237 platinum chemotherapy. Therefore, biomarkers predicting platinum response and recurrence in 238 second- or third-line chemotherapy should be defined by TFIp or progression-free survival from 239 treatment initiation for recurrence. After fourth-line therapy, the risk of recurrence and progression 240 during platinum chemotherapy is even higher and predictive biomarkers for platinum response might 241 be defined by the duration of continued platinum therapy. Ovarian cancer is unique as patients are 242 repeatedly administered platinum chemotherapy, even in cases of relapse, while good response to 243 platinum chemotherapy is expected. In the present study, we selected TFIp as an indicator of 244 predictive biomarkers for platinum response as platinum was administered as first-line therapy. 245 Biomarkers that can predict treatment response should be defined according to the specific line of 246 treatment.

The present study has several limitations. First, our results were based on dataset reanalysis and validation experiments using patients with recurrent cancer could not be conducted. Second, we did not include patients who received bevacizumab or PARPi as first-line therapy; therefore, whether the predictive models can be applied to these patients remains unclear. Circulating miRNAs can be

251	upregulated or downregulated by bevacizumab or PARPi [38, 39]. Further studies with larger,
252	independent groups are needed to determine predictive biomarkers for response to platinum in
253	combination with bevacizumab or PARPi. Third, although the expression of miRNAs in ovarian
254	cancer cell lines was considered, the origin of the circulating miRNAs measured in the present study
255	was unclear. Furthermore, the function of miRNAs in HGSOC should be evaluated in future studies.
256	In conclusion, we identified a circulating miRNA profile that predicted platinum response in
257	HGSOC before platinum chemotherapy. Accurate prediction of treatment response prior to initiation
258	can assist in determining appropriate treatment strategies, such as avoiding unnecessary treatments or
259	choosing additional treatments. Prospective studies are warranted to evaluate circulating miRNA
260	analysis for the translation of miRNA profiling into clinical care.
261	
262	Author Contribution
263	Study concept and design: Kazuhiro Suzuki., Akira Yokoi.
264	Provision of materials or patients: Kazuhiro Suzuki., Akira Yokoi., Kosuke Yoshida., Mitsuya
265	Ishikawa., Tomoyasu Kato.
266	Analysis and interpretation of data: Kazuhiro Suzuki., Akira Yokoi., Juntaro Matsuzaki., Kosuke
267	Yoshida.
268	Manuscript writing: Kazuhiro Suzuki., Akira Yokoi., Yoshida Kosuke., Juntaro Matsuzaki.
269	Critical review of the manuscript: All authors contributed.
270	Final approval of manuscript: All authors contributed.
271	
272	Conflict of Interest
273	None of the authors reported a conflict of interest
274	
275	Acknowledgment

276 No funding support of any kind was received for this study.

277

278 **References**

- [1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer
- 280 Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185
- 281 Countries. CA Cancer J Clin. 2021;71:209-49.
- [2] Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet.
- 283 2019;393:1240-53.
- [3] Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med.
- 285 2017;14:9-32.
- [4] Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al.
- 287 Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr
- 288 Canc Netw. 2021;19:191-226.
- [5] Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marme F, Lindemann K, et al. Maintenance
- 290 olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated
- with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial. Ann Oncol. 2023.
- [6] Takamatsu S, Nakai H, Yamaguchi K, Hamanishi J, Mandai M, Matsumura N. Time-Dependent
- 293 Changes in Risk of Progression During Use of Bevacizumab for Ovarian Cancer. JAMA Netw Open.
- 294 2023;6:e2326834.
- [7] Pujade-Lauraine E, Alexandre J. Update of randomized trials in recurrent disease. Ann Oncol.
- 296 2011;22 Suppl 8:viii61-viii4.
- [8] Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab
- 298 combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA
- open-label randomized phase III trial. J Clin Oncol. 2014;32:1302-8.
- 300 [9] Arend RC, Monk BJ, Shapira-Frommer R, Haggerty AF, Alvarez EA, Amit A, et al. Ofranergene

oblight of the former of the f
--

- 302 Randomized Controlled Phase III Trial (OVAL Study/GOG 3018). J Clin Oncol. 2023: JCO2202915.
- [10] van der Burg ME, Vergote I, Onstenk W, Boere IA, Leunen K, van Montfort CA, et al.
- 304 Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated
- treatment in patients with platinum-resistant ovarian cancer. Eur J Cancer. 2013;49:1254-63.
- 306 [11] Lortholary A, Largillier R, Weber B, Gladieff L, Alexandre J, Durando X, et al. Weekly
- 307 paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with
- resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs
- Nationaux pour l'Etude des Cancers Ovariens (GINECO). Ann Oncol. 2012;23:346-52.
- [12] Ambros V. The functions of animal microRNAs. Nature. 2004;431:350-5.
- [13] Esquela-Kerscher A, Slack FJ. Oncomirs microRNAs with a role in cancer. Nat Rev Cancer.
 2006;6:259-69.
- 313 [14] Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer
- of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol.
- 315 2007;9:654-9.
- 316 [15] Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker
- for cancer diagnosis and prognosis. Cancer Sci. 2010;101:2087-92.
- 318 [16] Yokoi A, Ochiya T. Exosomes and extracellular vesicles: Rethinking the essential values in
- cancer biology. Semin Cancer Biol. 2021;74:79-91.
- 320 [17] Yokoi A, Matsuzaki J, Yamamoto Y, Yoneoka Y, Takahashi K, Shimizu H, et al. Integrated
- extracellular microRNA profiling for ovarian cancer screening. Nat Commun. 2018;9:4319.
- 322 [18] Yoshida K, Yokoi A, Matsuzaki J, Kato T, Ochiya T, Kajiyama H, et al. Extracellular microRNA
- profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma. Cancer Sci.
- 324 2021;112:4977-86.
- 325 [19] Suzuki K, Yokoi A, Yoshida K, Kato T, Ochiya T, Yamamoto Y, et al. Preoperative serum

- 326 microRNAs as potential prognostic biomarkers in ovarian clear cell carcinoma. J Gynecol Oncol.
- 327 2023;34:e34.
- 328 [20] Okuno K, Kandimalla R, Mendiola M, Balaguer F, Bujanda L, Fernandez-Martos C, et al. A
- 329 microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant
- therapy in stage II and III colorectal cancer. Mol Cancer. 2023;22:13.
- [21] Wu A, Yen R, Grasedieck S, Lin H, Nakamoto H, Forrest DL, et al. Identification of
- 332 multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic
- myeloid leukemia at diagnosis. Leukemia. 2023.
- 334 [22] Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep
- sequencing data. Nucleic Acids Res. 2014;42:D68-73.
- [23] Yu X, Zhang X, Wang G, Wang B, Ding Y, Zhao J, et al. miR-206 as a prognostic and sensitivity
- biomarker for platinum chemotherapy in epithelial ovarian cancer. Cancer Cell Int. 2020;20:534.
- 338 [24] Compadre AJ, van Biljon LN, Valentine MC, Llop-Guevara A, Graham E, Fashemi B, et al.
- 339 RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer.
- 340 Clin Cancer Res. 2023;29:2466-79.
- [25] Ishida S, McCormick F, Smith-McCune K, Hanahan D. Enhancing tumor-specific uptake of the
 anticancer drug cisplatin with a copper chelator. Cancer Cell. 2010;17:574-83.
- 343 [26] Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, et al. Ovarian cancer stem
- cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer
- 345 Ther. 2011;10:325-35.
- [27] Latifi A, Abubaker K, Castrechini N, Ward AC, Liongue C, Dobill F, et al. Cisplatin treatment of
- 347 primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal
- stem cell-like profile. J Cell Biochem. 2011;112:2850-64.
- [28] Belanger F, Fortier E, Dube M, Lemay JF, Buisson R, Masson JY, et al. Replication Protein A
- 350 Availability during DNA Replication Stress Is a Major Determinant of Cisplatin Resistance in

- 351 Ovarian Cancer Cells. Cancer Res. 2018;78:5561-73.
- 352 [29] Zheng D, Huang X, Peng J, Zhuang Y, Li Y, Qu J, et al. CircMYOF triggers progression and
- facilitates glycolysis via the VEGFA/PI3K/AKT axis by absorbing miR-4739 in pancreatic ductal
- adenocarcinoma. Cell Death Discov. 2021;7:362.
- [30] Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets.
- 356 Nucleic Acids Res. 2020;48:D127-D31.
- [31] Khosravi N, Caetano MS, Cumpian AM, Unver N, De la Garza Ramos C, Noble O, et al. IL22
- 358 Promotes Kras-Mutant Lung Cancer by Induction of a Protumor Immune Response and Protection of
- 359 Stemness Properties. Cancer Immunol Res. 2018;6:788-97.
- 360 [32] Wang S, Yao Y, Yao M, Fu P, Wang W. Interleukin-22 promotes triple negative breast cancer
- 361 cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.
- 362 Biochem Biophys Res Commun. 2018;503:1605-9.
- [33] Wu D, Zhou J, Tan M, Zhou Y. LINC01116 regulates proliferation, migration, and apoptosis of
- keloid fibroblasts by the TGF-beta1/SMAD3 signaling via targeting miR-3141. Anal Biochem.

365 2021;627:114249.

- 366 [34] Zhu H, Gu X, Xia L, Zhou Y, Bouamar H, Yang J, et al. A Novel TGFbeta Trap Blocks
- 367 Chemotherapeutics-Induced TGFbeta1 Signaling and Enhances Their Anticancer Activity in
- 368 Gynecologic Cancers. Clin Cancer Res. 2018;24:2780-93.
- 369 [35] Gagno S, Poletto E, Bartoletti M, Quartuccio L, Romualdi C, Garziera M, et al. A TGF-beta
- associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian
- 371 cancer. Gynecol Oncol. 2020;156:233-42.
- [36] Ghezelayagh TS, Pennington KP, Norquist BM, Khasnavis N, Radke MR, Kilgore MR, et al.
- 373 Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or
- 374 BRCA2 mutations. Gynecol Oncol. 2021;160:786-92.
- [37] You B, Robelin P, Tod M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, et al. CA-125 ELIMination

- 376 Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results
- from the Phase II CHIVA Trial. Clin Cancer Res. 2020;26:4625-32.
- [38] Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, et al.
- 379 miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy
- treatment in breast cancer. Mol Oncol. 2019;13:2278-96.
- [39] Choi YE, Meghani K, Brault ME, Leclerc L, He YJ, Day TA, et al. Platinum and PARP Inhibitor
- 382 Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. Cell Rep.
- 383 2016;14:429-39.
- 384
- 385 Figure legends
- **Figure 1.**
- 387 Selection of patients and study design.
- 388 Flowchart of patients' selection. We identified a total of 442 patients with ovarian tumors with
- 389 preoperative serum microRNA profiles. Among them, 180 patients were diagnosed with high-grade
- 390 serous ovarian carcinoma. Finally, 180 patients were assessed in this study, after excluding 27
- 391 patients with stage I–II cancer, insufficient clinical information, and low-quality samples.
- **Figure 2.** ROC curves for each Model.
- ROC curves for prediction of TFIp by models using LASSO logistic regression analysis. The green
- colored area indicates the 95% confidence interval region. The details of the predictive model are
- shown in Supplementary Table 1.
- **Figure 3.** Development of the predictive TFIp models
- A. Dot plot for each Model. Patients were stratified based on the TFIp. *p* values were calculated byWelch's *t*-test.
- **B.** Model values for each in the same patient. Colored values indicate representative cases.
- 400

401 Supplementary figure legends

402 Supplementary figure 1.

- 403 Time course of ovarian cancer treatment and definition of treatment-free interval of platinum
- 404 Abbreviation: Ope, operation.

405 Supplementary figure 2.

- 406 A. Dot plot for each model. Dotted lines indicate linear regression model. R values were calculated
- 407 using Pearson's correlation coefficient.
- 408 B. Events over time were evaluated based on predictive models.
- 409 Kaplan–Meier curves showing patients stratified into high and low groups by each model with
- 410 cutoffs based on Youden index. *p* values were calculated using the generalized Wilcoxon test

Table 1

Clinical characteristics of 153 patients with high-grade serous carcinoma grouped according to TFIp.

	Number of patients (%)											
	Total (n = 153)		TFlp >	1 months	TFIp ≥ 6 months		TFIp ≥ 12 months		TFIp ≥ 36 months		<i>p</i> -value	
			(n = 143	(n = 143)		(n = 122)		(n = 84)				
Age, years-median (range)	60.2	(34–82)	60.3	(34–82)	60.5	(34–82)	59.21	(34–82)	56.8	(34–78)	0.418	
FIGO stage												
IIIC	96	(62.7)	92	(64.3)	81	(66.4)	56	(66.7)	18	(60.0)	0.981	
IVA	11	(7.2)	10	(7.0)	9	(7.4)	8	(9.5)	3	(10.0)		
IVB	46	(30.1)	41	(28.7)	32	(26.2)	20	(23.8)	9	(30.0)		
Neoadjuvant chemotherapy												
Yes	98	(62.7)	88	(61.5)	75	(61.5)	47	(56.0)	13	(43.3)	0.255	
No	55	(35.9)	55	(38.5)	47	(38.5)	37	(44.0)	17	(56.7)		
Surgery												
Complete	9	(5.9)	9	(6.3)	8	(6.6)	7	(8.3)	6	(20.0)	0.229	
Optimal	120	(78.4)	115	(80.4)	99	(81.1)	70	(83.3)	21	(70.0)		
Sub-optimal	24	(15.7)	19	(13.3)	15	(12.3)	7	(8.3)	3	(10.0)		
Recurrence												
Yes	132	(86.3)	122	(85.3)	101	(82.8)	63	(75.0)	10	(33.3)	< 0.001	
No	21	(13.7)	21	(14.7)	21	(17.2)	21	(25.0)	20	(66.7)		
TFIp, months-median (range)	22.6	(0–130)	24.18	(2–130)	27.82	(6–130)	36.49	(12–130)	65.70	(36–130)	< 0.001	
PFS, months-median (range)	28.3	(4–136)	29.76	(5–136)	33.38	(10–136)	42.35	(16–136)	72.50	(40–136)	< 0.001	
OS, months-median (range)	55.8	(8–142)	57.84	(8–142)	64.16	(13–142)	73.90	(22–142)	86.03	(49–142)	< 0.001	

Note: Data are shown as n (%) unless otherwise noted.

Abbreviation: PFS, progression-free survival. OS, overall survival.

Table2.

Discrimination accuracy of each diagnostic model

Model No.	TFlp	miRNAs (n)	Sensitivity	Specificity	Accuracy	AUC	(95%CI)	p(DeLo	ong's test)
1-1	>1 month	8	0.755	1.000	0.771	0.903	(0.832 - 0.974)		
1-2	>1 month	9	0.783	1.000	0.797	0.928	(0.871 – 0.985)	0.041	(vs. 1-1)
1-3 (Model TFIp > 1 month)	>1 month	10	0.818	1.000	0.830	0.944	(0.896 – 0.992)	0.047	(vs. 1-2)
1-4	>1 month	11	0.818	1.000	0.830	0.961	(0.921 – 1.000)	0.061	(vs. 1-3)
1-5	>1 month	13	0.951	0.900	0.948	0.967	(0.930 – 1.000)	0.179	(vs. 1-4)
1-6	>1 month	14	0.986	0.900	0.980	0.980	(0.949 – 1.000)	0.509	(vs. 1-5)
1-7	>1 month	15	0.993	0.900	0.987	0.985	(0.959 – 1.000)	0.219	(vs. 1-6)
1-8	>1 month	17	0.993	0.900	0.987	0.986	(0.963 – 1.000)	0.414	(vs. 1-7)
1-9	>1 month	18	0.937	1.000	0.941	0.990	(0.976 – 1.000)	0.436	(vs. 1-8)
6-1(Model TFIp ≥ 6 months)	≥6 months	1	0.467	0.774	0.529	0.637	(0.526 – 0.748)		
12-1(Model TFIp ≥ 1	12 ≥12 months	Λ	0 706	0 588	0.654	0 705	(0 622 - 0 787)		
months)		4	0.700	0.500	0.054	0.705	(0.022 - 0.707)		
12-2	≥12 months	5	0.741	0.574	0.667	0.713	(0.632 – 0.794)	0.155	(vs. 12-1)
12-3	≥12 months	6	0.647	0.677	0.660	0.721	(0.642 – 0.801)	0.059	(vs. 12-2)
12-4	≥12 months	7	0.894	0.441	0.693	0.726	(0.647 – 0.806)	0.252	(vs. 12-3)
12-5	≥12 months	8	0.753	0.588	0.698	0.736	(0.658 – 0.815)	0.110	(vs. 12-4)
36-1	≥36 months	25	0.867	0.829	0.837	0.901	(0.842 – 0.960)		(vs. 36-14)
36-2	≥36 months	26	0.867	0.878	0.876	0.914	(0.859 – 0.970)	0.007	(vs. 36-15)
36-3	≥36 months	29	0.900	0.854	0.863	0.917	(0.862 – 0.971)	0.046	(vs. 36-16)
36-4	≥36 months	30	0.900	0.862	0.870	0.920	(0.867 – 0.974)	0.014	(vs. 36-17)
36-5	≥36 months	31	0.900	0.870	0.876	0.926	(0.875 – 0.978)	0.005	(vs. 36-18)
36-6	≥36 months	33	0.900	0.894	0.895	0.931	(0.881 – 0.980)	0.020	(vs. 36-19)
36-7(Model TFIp ≥ 3	36	36	0.900	0.894	0.895	0.938	(0.891 – 0.985)	0.009	(vs. 36-20)
months)	≥30 months								

Patients with ovarian tumor who were treated at National Cancer Center Hospital and registered in the National Cancer Center Biobank between 2008 and 2016

Patients	Patients with ovarian tumor (n = 442)									
	→	Exclude	(n = 262)							
		Clear cell	(n = 68)							
		Endometrioid	(n = 48)							
		Mucinous	(n = 16)							
		Low-grade serous	s (n = 9)							
		Others	(n = 26)							
		Benign/borderline	(n = 95)							
	T Contraction of the second seco									

Patients with high-grade serous carcinoma (n = 180)

Т

	→ Exclude	(n = 27)
	Stage I	(n = 4)
	Stage II	(n = 10)
	Insufficient information	(n = 11)
	Low-quality samples	(n = 2)
· · · · · · · · · · · · · · · · · · ·		
Assessed patients ((n = 153)	



Figure 3



Supplementary figure 1





Treatment free interval of platinum (months)

Supplementary Table1. Detail of predictive model

Model No.	Predictive model Y
1-1	(-0.08022 × miR-1228-5p) + (-0.16169 × miR-1273g-3p) + (0.23871 × miR-3917) + (-0.0793 × miR-3940-5p) + (-0.72774 ×
	miR-4739) + (0.3835 × miR-498) + (0.01805 × miR-6088) + (0.04429 × miR-6872-3p) + 10.07757

1-2 (-0.305235 × miR-1228-5p) + (-0.2308 × miR-1273g-3p) + (0.271838 × miR-3917) + (-0.13299 × miR-3940-5p) + (0.005181 × miR-4708-3p) + (-0.89869 × miR-4739) + (0.435498 × miR-498) + (0.231217 × miR-6088) + (0.085698 × miR-6872-3p) + 12.543835

- 1-3 (Model TFIp $(-0.43074 \times miR-1228-5p) + (-0.2713 \times miR-1273g-3p) + (0.2881 \times miR-3917) + (-0.15449 \times miR-3940-5p) + (0.03679 \times miR-4708-3p) + (-1.00381 \times miR-4739) + (-0.0285 \times miR-486-5p) + (0.47157 \times miR-498) + (0.35716 \times miR-6088) + (0.09762 \times miR-6872-3p) + 13.9039$
- 1-4 $(-0.58016 \times \text{miR}-1228-5p) + (-0.307222 \times \text{miR}-1273g-3p) + (0.330061 \times \text{miR}-3917) + (-0.171047 \times \text{miR}-3940-5p) + (0.092346 \times \text{miR}-4708-3p) + (-1.1506 \times \text{miR}-4739) + (-0.142806 \times \text{miR}-486-5p) + (0.526739 \times \text{miR}-498) + (0.007233 \times \text{miR}-6087) + (0.525026 \times \text{miR}-6088) + (0.107553 \times \text{miR}-6872-3p) + 15.494438$
- 1-5 $(-0.646803 \times miR-1228-5p) + (-0.313229 \times miR-1273g-3p) + (0.030311 \times miR-371a-5p) + (0.34458 \times miR-3917) + (-0.165331 \times miR-3940-5p) + (0.002726 \times miR-4449) + (0.110589 \times miR-4708-3p) + (-1.211764 \times miR-4739) + (-0.178796 \times miR-486-5p) + (0.545045 \times miR-498) + (0.032721 \times miR-6087) + (0.569194 \times miR-6088) + (0.11015 \times miR-6872-3p) + 15.78128$

1-6 $(-0.90035 \times miR-1228-5p) + (-0.33003 \times miR-1273g-3p) + (-0.01715 \times miR-17-3p) + (0.13348 \times miR-371a-5p) + (0.36831 \times miR-3917) + (0.05396 \times miR-3928-3p) + (-0.20548 \times miR-3940-5p) + (0.15664 \times miR-4449) + (0.16038 \times miR-4708-3p) + (-1.45235 \times miR-4739) + (-0.27004 \times miR-486-5p) + (0.57565 \times miR-498) + (0.74862 \times miR-6088) + (0.11426 \times miR-6872-3p) + 18.19444$

1-7 $(-0.002713 \times miR-1181) + (-0.991055 \times miR-1228-5p) + (-0.328202 \times miR-1273g-3p) + (-0.037427 \times miR-17-3p) + (0.169809 \times miR-371a-5p) + (0.377633 \times miR-3917) + (0.079125 \times miR-3928-3p) + (-0.222452 \times miR-3940-5p) + (0.196208 \times miR-4449) + (0.17659 \times miR-4708-3p) + (-1.538496 \times miR-4739) + (-0.292685 \times miR-486-5p) + (0.58726 \times miR-498) + (0.80589 \times miR-6088) + (0.112803 \times miR-6872-3p) + 19.075818$

1-8 $(-0.009675 \times miR-1181) + (-1.050908 \times miR-1228-5p) + (-0.331264 \times miR-1273g-3p) + (-0.0542 \times miR-17-3p) + (0.027084 \times miR-3158-5p) + (0.19372 \times miR-371a-5p) + (0.383034 \times miR-3917) + (0.111428 \times miR-3928-3p) + (-0.23688 \times miR-3940-5p) + (0.217287 \times miR-4449) + (0.188668 \times miR-4708-3p) + (-1.673817 \times miR-4739) + (-0.317227 \times miR-486-5p) + (0.596774 \times miR-498) + (0.854739 \times miR-6088) + (-0.007404 \times miR-671-5p) + (0.110257 \times miR-6872-3p) + 20.442601$

1-9 $(-0.022898 \times miR-1181) + (-1.163292 \times miR-1228-5p) + (-0.33282 \times miR-1273g-3p) + (-0.088704 \times miR-17-3p) + (0.073399 \times miR-3158-5p) + (0.245542 \times miR-371a-5p) + (0.397722 \times miR-3917) + (0.176185 \times miR-3928-3p) + (-0.259566 \times miR-3940-5p) + (0.247176 \times miR-4449) + (0.007695 \times miR-4675) + (0.211683 \times miR-4708-3p) + (-1.931075 \times miR-4739) + (-0.363093 \times miR-486-5p) + (0.61721 \times miR-498) + (0.948609 \times miR-6088) + (-0.027716 \times miR-671-5p) + (0.103336 \times miR-6872-3p) + 22.921317$

6-1 (Model TFIp (0.04331 × miR-4708-3p) + 1.0617

 \geq 6 months)

12-1 (**Model TFIp** (-0.0426 × miR-3141) + (0.01861 × miR-3928-3p) + (0.0129 × miR-6766-5p) + (0.0094 × miR-7108-3p) + 0.31159 ≥ **12** months)

12-2 (0.005506 × miR-1254) + (-0.233162 × miR-3141) + (0.108505 × miR-3928-3p) + (0.052679 × miR-6766-5p) + (0.046921 × miR-7108-3p) + 0.771309

12-3 (0.024523 × miR-1254) + (-0.370958 × miR-3141) + (0.158208 × miR-3928-3p) + (0.074012 × miR-6766-5p) + (-0.008133 × miR-6869-5p) + (0.073977 × miR-7108-3p) + 1.267906

12-4 $(0.030583 \times miR-1254) + (-0.414682 \times miR-3141) + (0.174476 \times miR-3928-3p) + (-0.002631 \times miR-6722-3p) + (0.080808 \times miR-6766-5p) + (-0.026614 \times miR-6869-5p) + (0.085647 \times miR-7108-3p) + 1.635997$

12-5 $(0.041917 \times miR-1254) + (-0.492179 \times miR-3141) + (0.201249 \times miR-3928-3p) + (0.003775 \times miR-4322) + (-0.052872 \times miR-6722-3p) + (0.098461 \times miR-6766-5p) + (-0.05535 \times miR-6869-5p) + (0.105975 \times miR-7108-3p) + 2.590153$

36-1

(-0.0085052×miR-1254)	+	(-0.2186654×miR-187-5p)	+	(-0.0117764×miR-1908-3p) + (0.0192129×miR-191-5p)	+
(-0.0818024×miR-3141)	+	(-0.4142278×miR-3197)	+	(0.1690961×miR-320a) + (0.0526361×miR-342-5p)	+
(0.0145941×miR-4429)	+	(0.3025396×miR-4447)	+	(-0.3635017×miR-4463) + (0.0458145×miR-4515)	+
(0.0542341×miR-4675)	+	(0.0004475×miR-4732-5p)	+	- (0.0496912×miR-486-5p) + (0.2732072×miR-557)	+
(-0.0545019×miR-642a-3	3p) -	+ (0.0599133×miR-6766-3p)	+	(-0.1072596×miR-6799-5p) + (-0.0986669×miR-6808-5p)	+
(-0.4353737×miR-6858-5	;р) +	(-0.0400214×miR-718) + (-0.	.33	17855×miR-8089) + (-0.0853479×miR-887-3p) + 11.2233496	5

(-0.0100718×miR-1254)	+	(-0.2774778×miR-187-5p)	+	(0.0235554×miR-191-5p)	+	(-0.0858186×miR-3141)	+
(-0.4645236×miR-3197)	+	(0.1909219×miR-320a)	+	(0.0730775×miR-342-5p)	+	(0.038733×miR-4429)	+
(0.3572965×miR-4447)	+	(0.0018236×miR-4449)	+	(-0.566197×miR-4463)	+	(0.0426433×miR-4515)	+
(0.139225×miR-4675)	+	(0.0015923×miR-4732-5p)	+	(0.060029×miR-486-5p)	+	(0.3794857×miR-557)	+
(0.0006165×miR-6088)	+ (-0.0948298×miR-642a-3p)	+ (().0941779×miR-6766-3p)	+ (-	0.1842586×miR-6799-5p)	+
(-0.1423826×miR-6808-5	p)	+ (-0.4693842×miR-6858-	5p)	+ (-0.1065337×miR-718)	+	(-0.4048481×miR-8089)	+
(-0.0975639×miR-887-3p) + '	14.2793853					

(-0.010512×miR-1254) (-0.296032×miR-187-5p) (0.025459×miR-191-5p) (-0.085324×miR-3141) + + + + (-0.480216×miR-3197) (0.197352×miR-320a) (0.07997×miR-342-5p) (0.008677×miR-3928-3p) + + + + (0.045585×miR-4429) + (0.373793×miR-4447) + (0.005308×miR-4449) + (-0.629153×miR-4463) + (0.040963×miR-4515) + (0.001092×miR-4640-5p) (0.161587×miR-4675) (0.001617×miR-4732-5p) (0.06312×miR-486-5p) + + + + (0.412694×miR-557) (0.010712×miR-6088) (-0.108938×miR-642a-3p) (0.102524×miR-6766-3p) + + + + (-0.211281×miR-6799-5p) + (-0.161989×miR-6808-5p) + (0.003912×miR-6842-5p) + (-0.48001×miR-6858-5p) + (-0.128392×miR-718) + (-0.424643×miR-8089) + (-0.101338×miR-887-3p) + 15.160137

(-0.0108976×miR-1254)	+	(-0.313461×miR-187-5p)	+	+ (0.0274867×miR-191-5p)	+	(-0.0877817×miR-3141)	+
(-0.4953478×miR-3197)	+	(0.2058604×miR-320a)	+	(0.0849152×miR-342-5p) +	((0.0191089×miR-3928-3p)	+
(0.0006009×miR-4419b)	+	(0.0505798×miR-4429)	1	+ (0.3888059×miR-4447)	+	(0.008254×miR-4449)	+
(-0.702695×miR-4463)	+	(0.0379672×miR-4515)	+	(0.0200086×miR-4640-5p)	+	(0.1783874×miR-4675)	+
(0.0007739×miR-4732-5p)) -	+ (0.0678916×miR-486-	5p)	+ (0.4450908×miR-557)	+	(0.0250757×miR-6088)	+
(-0.1206386×miR-642a-3p) +	(0.1110271×miR-6766-3	с) -	+ (-0.2438217×miR-6799-5p)	+	(-0.1850382×miR-6808-5p)	+

36-3

36-4

36-2

 $(0.0141535 \times miR-6842-5p) + (-0.4881161 \times miR-6858-5p) + (-0.1534442 \times miR-718) + (-0.4433555 \times miR-8089) + (-0.1063541 \times miR-887-3p) + 16.0608247$

36-5 (-0.011304×miR-1254) (-0.330556×miR-187-5p) (0.029674×miR-191-5p) (-0.090643×miR-3141) + + + + $(-0.510819 \times miR-3197) + (0.21427 \times miR-320a) + (0.0897 \times miR-342-5p) + (0.029023 \times miR-3928-3p) + (0.003306 \times miR-4419b)$ + $(0.053975 \times miR-4429) + (0.403336 \times miR-4447) + (0.011158 \times miR-4449) + (-0.774378 \times miR-4463) + (0.034354 \times miR-4515) + (0.011158 \times miR-4449) + (-0.774378 \times miR-4463) + (0.034354 \times miR-4515) + (0.011158 \times miR-4449) + (-0.774378 \times miR-4463) + (0.034354 \times miR-4515) + (0.011158 \times miR-4449) + (-0.774378 \times miR-4463) + (0.034354 \times miR-4515) + (0.011158 \times miR-4449) + (-0.774378 \times miR-4463) + (0.034354 \times miR-4515) + (0.011158 \times miR-4449) + (-0.774378 \times miR-4463) + (0.034354 \times miR-4515) + (0.011158 \times miR-4463) + (0.011158 \times miR-4463) + (0.034354 \times miR-4515) + (0.011158 \times miR-4463) + (0.011158 \times miR-4463) + (0.011158 \times miR-4663) + (0.034354 \times miR-4515) + (0.011158 \times miR-4563) + (0.011158 \times miR-4563$ $(0.037603 \times miR-4640-5p) + (0.195169 \times miR-4675) + (0.072194 \times miR-486-5p) + (0.4778 \times miR-557) + (0.039272 \times miR-6088) + (0$ $(-0.132742 \times miR-642a-3p) + (0.118471 \times miR-6766-3p) + (-0.279327 \times miR-6799-5p) + (-0.208812 \times miR-6808-5p) +$ $(0.023642 \times miR-6842-5p) + (-0.497048 \times miR-6858-5p) + (0.001925 \times miR-6877-5p)$ + (-0.17823×miR-718) + (-0.461239×miR-8089) + (-0.111737×miR-887-3p) + (0.004446×miR-939-5p) + 16.976658

 $(-0.011751 \times miR-1254) + (-0.347334 \times miR-187-5p) + (0.032074 \times miR-191-5p) + (-0.0963 \times miR-3141) + (-0.527889 \times miR-3197) \\ + (0.223442 \times miR-320a) + (0.094826 \times miR-342-5p) + (0.036391 \times miR-3928-3p) + (0.005184 \times miR-4419b) + \\ (0.053273 \times miR-4429) + (0.417271 \times miR-4447) + (0.015554 \times miR-4449) + (-0.843683 \times miR-4463) + (-0.00283 \times miR-4484) + \\ (0.029242 \times miR-4515) + (0.053746 \times miR-4640-5p) + (0.212297 \times miR-4675) + (0.076018 \times miR-486-5p) + (0.511782 \times miR-557) \\ + (0.053403 \times miR-6088) + (-0.144789 \times miR-642a-3p) + (0.123975 \times miR-6766-3p) + (-0.319733 \times miR-6799-5p) + \\ (-0.231024 \times miR-6808-5p) + (0.032697 \times miR-6842-5p) + (-0.505911 \times miR-6858-5p) + (0.001763 \times miR-6877-5p) + \\ (0.007005 \times miR-7108-3p) + (-0.202289 \times miR-718) + (-0.479487 \times miR-8089) + (-0.117001 \times miR-887-3p) + \\ (0.022773 \times miR-939-5p) + 17.907449$

36-7 (Model TFIp	$(-0.0125433 \times \text{miR}-1181) + (0.1)$	067349×miR-1254) +	(0.0015947×miR-1268b) +	(-0.3771727×miR-187-5p)	+
≥ 36 months)	(0.0360527×miR-191-5p) + (-0).0984009×miR-3141) +	(0.0233745×miR-3195) +	- (-0.5606837×miR-3197)	+
	(0.2415774×miR-320a) + (0.10)46963×miR-342-5p) +	(0.0502296×miR-3928-3p)	+ (0.0009486×miR-422a)	+
	(0.0050783×miR-4419b) + (0).05179×miR-4429) +	(0.4470169×miR-4447) +	(0.0210486×miR-4449)	+
	(-0.9951068×miR-4463) + (-0.6	0335096×miR-4484) +	(0.0152364×miR-4515) +	(0.0870314×miR-4640-5p)	+

36-6

 $(0.2338915 \times miR-4675) + (0.0864322 \times miR-486-5p) + (0.5827542 \times miR-557) + (0.0782236 \times miR-6088) + (-0.1712249 \times miR-642a-3p) + (0.1380852 \times miR-6766-3p) + (-0.3991616 \times miR-6799-5p) + (-0.2738122 \times miR-6808-5p) + (0.0531576 \times miR-6842-5p) + (-0.5248665 \times miR-6858-5p) + (0.033589 \times miR-7108-3p) + (-0.2512049 \times miR-718) + (-0.5161003 \times miR-8089) + (-0.1219326 \times miR-887-3p) + (0.0626341 \times miR-939-5p) + 19.9189978$

Supplementary Table 2.

AUC for all subgroups based on each model.

	Predict TFIp				
Model No.	> 1 month	≥ 6 months	≥ 12 months	≥ 36 months	
Model TFIp > 1 month	0.944	0.663	0.603	0.618	
Model TFIp ≥ 6 months	0.631	0.637	0.570	0.563	
Model TFIp ≥ 12 months	0.757	0.698	0.705	0.659	
Model TFIp ≥ 36 months	0.624	0.641	0.645	0.938	

Note: Data are shown as AUC unless otherwise noted.